Study of Accelerated Partial Breast Irradiation Using Stereotactic Body Radiation Therapy in Women With Early Breast Cancer
Led by RPCR, Inc. · Updated on 2022-08-05
200
Participants Needed
2
Research Sites
145 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the safety and effectiveness of Accelerated Partial Breast Irradiation APBI using a specialized radiation technique called Stereotactic Body Radiation Therapy SBRT in women with certain types of breast cancer. This observational study focuses on women aged 50 to 100 with low to intermediate grade ductal carcinoma in situ or invasive ductal carcinoma, aiming to assess outcomes over a five-year follow-up period.
Participants will receive a targeted radiation dose of 30 Gy divided into five treatments, delivered over alternating days within 5 to 10 days. Before treatment, fiducial markers are placed to guide precise radiation targeting. Imaging techniques such as CT scans, MRI, and PET may be used for motion assessment, and different equipment setups like gantry-based linear accelerators or robotic systems CyberKnife are utilized depending on the case. The radiation targets the tumor cavity with defined margins while protecting surrounding organs and tissues.
During the study, participants will undergo regular imaging and assessments to monitor breast appearance, acute toxicities within 6 weeks, and late side effects up to 5 years. Researchers will measure cosmetic outcomes using standardized scales and record any adverse events related to treatment. The study includes detailed dosimetry and safety monitoring to evaluate the treatments impact over time.
CONDITIONS
Brief Title
Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)
Research Team
M
Mark Perman, MD
D
Debra Freeman, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Lumpectomy cavity must be less than 30% of whole breast volume
You will not qualify if you...
Lobular histology
Angiolymphatic invasion
Multiple foci of disease
Lymphovascular invasion
Active lupus or sarcoidosis
Distant metastases
Non-epithelial malignancies
Synchronous contralateral breast cancer
Grade 2 or higher oncoplastic surgery
Ipsilateral pacemaker
Ipsilateral breast implant
Neoadjuvant chemotherapy
Prior ipsilateral breast cancer or thoracic radiation
Poor breast integrity
Paget's Disease of the nipple
Pregnant patients
Severe cardiac, pulmonary, or liver diseases
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to several weeks prior to treatment
Participants who have undergone breast conservation surgery with fiducial markers placed are observed as part of standard care to define the treatment area.
Imaging visits including CT scans with possible MRI and PET as part of simulation
Treatment
Duration - 5 to 10 days
Participants receive stereotactic body radiation therapy (SBRT) consisting of 5 fractions of radiation delivered on alternating days to the breast tumor cavity.
5 treatment visits over 5 to 10 days
Long-term Monitoring
Duration - Up to 60 months
Participants are followed over months to years to assess breast cosmesis, acute and late toxicities, and overall safety after radiation therapy.
Periodic follow-up visits over 2 to 5 years
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Phase III Study Evaluating Magic Ink Tattoos for Radiation Treatment in Women with Breast Cancer
Study of Accelerated Partial Breast Irradiation Using Stereotactic Body Radiation Therapy in Women With Early Breast Cancer
Evaluation of Intralesional CAN1012 Injection for Safety in Pre-Malignant Ductal and Lobular Carcinoma in Situ
Evaluating Active Surveillance and Hormonal Therapies for Early Breast Cancer DCIS with Novel Endocrine Treatments
Study of Inflammation and Social Factors in Women with Breast Cancer
Neoadjuvant Hormone Therapy with Tamoxifen or Anastrozole for Women Over 40 with Extensive Ductal Carcinoma In Situ Facing Mastectomy
Evaluating a New Cavity Marking Technique During Breast Conservation Surgery with Oncoplastic Reconstruction to Improve Radiotherapy and Re-excision Accuracy in Breast Cancer Patients
Phase II Study of Preoperative Partial Breast Irradiation for Early-Stage Breast Cancer Evaluating Treatment Response, Side Effects, and Cosmetic Results
Study of a Prototype MUC1 Vaccine With Hormone Therapy to Prevent Disease Progression in Women With Ductal Carcinoma In Situ
Study of Partial Breast Irradiation After Breast-Conserving Surgery Without Lymph Node Removal in Women 40 and Older With Early-Stage Breast Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Response to "Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation" (Int J Radiat Oncol Biol Phys 2010;76:71-78) and "Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation" Int J Radiat Oncol Biol Phys 2009;75:1290-1296).
Preliminary Results of a Phase 1 Dose-Escalation Trial for Early-Stage Breast Cancer Using 5-Fraction Stereotactic Body Radiation Therapy for Partial-Breast Irradiation.
Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial.
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Charlotte E Coles, Clare L Griffin, Anna M Kirby...
External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
Timothy J Whelan, Jim A Julian, Tanya S Berrang...
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
Frank A Vicini, Reena S Cecchini, Julia R White...